Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question

Immunotherapy has redefined the treatment of cancer patients and it is constantly generating new advances and approaches. Among the multiple options of immunotherapy, bispecific antibodies (bsAbs) represent a novel thoughtful approach. These drugs integrate the action of the immune system in a strat...

Full description

Bibliographic Details
Main Authors:	Camila Ordóñez-Reyes, Juan Esteban Garcia-Robledo, Diego F. Chamorro, Andrés Mosquera, Liliana Sussmann, Alejandro Ruiz-Patiño, Oscar Arrieta, Lucia Zatarain-Barrón, Leonardo Rojas, Alessandro Russo, Diego de Miguel-Perez, Christian Rolfo, Andrés F. Cardona
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	Pharmaceutics
Subjects:	bispecific antibodies immunotherapy immune restoration cancer therapy
Online Access:	https://www.mdpi.com/1999-4923/14/6/1243

Similar Items

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
by: Gihoon You, et al.
Published: (2021-07-01)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
by: Jing Wei, et al.
Published: (2022-10-01)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
by: Brian H. Santich, et al.
Published: (2020-12-01)

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01)

A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023
by: Jing Wei, et al.
Published: (2024-01-01)

Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017-04-01)

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
by: Xiaohan Guo, et al.
Published: (2023-12-01)

Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
by: Junjun Fu, et al.
Published: (2023-03-01)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
by: Zheng Tian, et al.
Published: (2021-05-01)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
by: Margaux Lejeune, et al.
Published: (2020-05-01)

Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells
by: Kamal Kishore Joshi, et al.
Published: (2019-10-01)

The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
by: Rita Tavarozzi, et al.
Published: (2022-02-01)

Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
by: Maciej Kujawski, et al.
Published: (2019-09-01)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
by: Gregorio Barilà, et al.
Published: (2021-01-01)

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
by: Liang J, et al.
Published: (2021-09-01)

The landscape of bispecific T cell engager in cancer treatment
by: Shujie Zhou, et al.
Published: (2021-05-01)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
by: Shih-Feng Cho, et al.
Published: (2022-10-01)

Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies
by: Cholpon Tilegenova, et al.
Published: (2020-01-01)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)

Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018-01-01)

Bispecific antibodies and their use in applied research
by: Harshit Verma, et al.
Published: (2012-01-01)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
by: Alessandro Satta, et al.
Published: (2019-10-01)

Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5
by: Frank Breitling, et al.
Published: (2013-05-01)

Bispecific antibodies: a novel approach for targeting prominent biomarkers
by: Akshita Gupta, et al.
Published: (2020-11-01)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
by: Gabriele Antonarelli, et al.
Published: (2021-08-01)

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
by: Joanie Del Bano, et al.
Published: (2015-12-01)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
by: Yan Yang, et al.
Published: (2021-07-01)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
by: Zakaria Grada, et al.
Published: (2013-01-01)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
by: Roa Alsajjan, et al.
Published: (2023-09-01)

Bispecific Antibodies Progression in Malignant Melanoma
by: Juan Tang, et al.
Published: (2022-03-01)

Bispecific antibody drug conjugates: Making 1+1>2
by: Yilin Gu, et al.
Published: (2024-05-01)

Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs
by: Yuanyuan SONG, et al.
Published: (2022-09-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
by: Robert L. Kruse, et al.
Published: (2017-12-01)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
by: Omar Castaneda-Puglianini, et al.
Published: (2021-09-01)

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
by: Rui Sun, et al.
Published: (2021-06-01)

Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules
by: Janine Dilchert, et al.
Published: (2022-05-01)

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy
by: Yun Yang, et al.
Published: (2023-12-01)

Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
by: Giulio Cassanello, et al.
Published: (2024-12-01)